PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis
- First Posted Date
- 2020-11-10
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 120
- Registration Number
- NCT04624230
- Locations
- 🇮🇹
A.O.U. Federico II, Napoli, Naples, Italy
🇮🇹ASST Papa Giovanni XXIII Epatologia e Gastroenterologia Pediatrica e dei Trapianti, Bergamo, BG, Italy
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
Study To Evaluate The Effect Of Two Steady State Doses of PF 06882961 On Rosuvastatin And Midazolam Pharmacokinetics In Otherwise Healthy Adult Participants With Obesity
- First Posted Date
- 2020-11-09
- Last Posted Date
- 2023-12-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 16
- Registration Number
- NCT04621227
- Locations
- 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States
Anticoagulation in Patients With Venous Thromboembolism and Cancer
- Conditions
- NeoplasmsEmbolism
- Interventions
- First Posted Date
- 2020-11-06
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1
- Registration Number
- NCT04618913
- Locations
- 🇬🇧
Pfizer Investigational Site, London, United Kingdom
A 12-WEEK TITRATE STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACODYNAMICS OF PF-06882961 IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND IN NON-DIABETIC ADULTS WITH OBESITY
- First Posted Date
- 2020-11-05
- Last Posted Date
- 2022-12-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 151
- Registration Number
- NCT04617275
- Locations
- 🇺🇸
Emerson Clinical Research Institute, Washington, District of Columbia, United States
🇺🇸Clinical Neuroscience Solutions, Inc., Memphis, Tennessee, United States
🇺🇸Solaris Clinical Research, Meridian, Idaho, United States
STUDY TO COMPARE PHARMACOKINETICS (PK) OF SINGLE ORAL DOSES OF DIFFERENT PF-06882961 FORMULATIONS IN PARTICIPANTS WHO ARE OVERWEIGHT OR HAVE OBESITY
- First Posted Date
- 2020-11-04
- Last Posted Date
- 2022-04-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 31
- Registration Number
- NCT04616339
- Locations
- 🇧🇪
Brussels Clinical Research Unit, Brussels, Bruxelles-capitale, Région DE, Belgium
STUDY OF PF-06882961 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WITH VARYING DEGREES OF RENAL IMPAIRMENT AND PARTICIPANTS WITHOUT RENAL IMPAIRMENT
- Conditions
- Diabetes Mellitus, Type 2HealthyRenal Impairment
- Interventions
- First Posted Date
- 2020-11-04
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 42
- Registration Number
- NCT04616027
- Locations
- 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸Prism Research LLC dba Nucleus Network, Saint Paul, Minnesota, United States
🇺🇸University of Miami Hospital, Miami, Florida, United States
PCV13 Effectiveness Study Against Hospitalised VT Pneumococcal CAP in Adults 60 Years and Older
- Conditions
- Community Acquired Pneumonia (CAP)
- Interventions
- Diagnostic Test: Urine sample collectionDiagnostic Test: Saliva collection
- First Posted Date
- 2020-11-03
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1821
- Registration Number
- NCT04613375
- Locations
- 🇪🇸
Hospital Universitarios De Getafe, Getafe, Madrid, Spain
🇪🇸Hospital Universitario Severo Ochoa, Leganés, Madrid, Spain
🇪🇸Hospital Universitario Fundación Alcorcón, Alcorcón, Spain
Real World Utilization and Outcomes With Dacomitinib First Line Treatment for EGFR Mutation-positive Advanced Non Small Cell Lung Cancer Among Asian Patients - A Multi Center Chart Review
- First Posted Date
- 2020-10-30
- Last Posted Date
- 2025-05-31
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 307
- Registration Number
- NCT04609319
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
- Conditions
- Neoplasms
- Interventions
- First Posted Date
- 2020-10-29
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 827
- Registration Number
- NCT04607421
- Locations
- 🇺🇸
Siteman Cancer Center - North County, Florissant, Missouri, United States
🇺🇸Mayo Clinic Hospital, Phoenix, Arizona, United States
🇺🇸Mayo Clinic in Arizona - Scottsdale, Scottsdale, Arizona, United States
Etrasimod Versus Placebo for the Treatment of Moderately Active Ulcerative Colitis
- First Posted Date
- 2020-10-29
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 234
- Registration Number
- NCT04607837
- Locations
- 🇺🇸
Tampa Bay Endoscopy Center, Tampa, Florida, United States
🇺🇸Pulmonary and Critical Care Medicine Associates (PFT only), Lemoyne, Pennsylvania, United States
🇺🇸Harrisburg Eye Associates (OCT only), Harrisburg, Pennsylvania, United States